Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo

International Journal of Urology

Volumn 14, Issue 9, 2007, Pages 838-845

  Gao, Dexuan ^a   Xia, Qinghua ^a   Lv, Jiaju ^a   Zhang, Hui ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Histone deacetylase inhibitors; Prostate cancer; Valproic acid; Vascular endothelial growth factor

Indexed keywords

HISTONE DEACETYLASE; VALPROIC ACID; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG MECHANISM; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

ACETYLATION; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; VALPROIC ACID; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548165712     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01823.x     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J. Clin. 2006 56:106 30.
2. Xiang YB, Zhang W, Gao LF et al. [Methods for time trend analysis of cancer incidence rates]. Zhonghua Liu Xing Bing Xue Za Zhi 2004 25:173 7.
3. Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993 72:3888 95.
4. Diaz M, Patterson SG. Management of androgen-independent prostate cancer. Cancer Control 2004 11:364 73.
5. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000 92:1210 16.
6. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995 377:454 7.
7. Horlein AJ, Naar AM, Heinzel T et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995 377:397 404.
8. Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev. 1999 9:140 7.
9. Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002 1:287 99.
10. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 2000 92:1210 16.
11. Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription? Cell 1997 89:325 8.
12. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002 3:415 28.
13. Mei S, Ho AD, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int. J. Oncol. 2004 25:1509 19.
14. el-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993 75:817 25.
15. Weinberg WC, Denning MF. P21Waf1 control of epithelial cell cycle and cell fate. Crit. Rev. Oral Biol. Med. 2002 13:453 64.
16. Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F, Ringert RH. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int. J. Oncol. 2004 24:25 31.
17. Kramer OH, Zhu P, Ostendorff HP et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 2003 22:3411 20.
18. Xia Q, Sung J, Chowdhury W et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006 66:7237 44.
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100:57 70.
20. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene. 2000 19:6122 9.
21. Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res. 2001 61:1477 85.
22. Rossig L, Li H, Fisslthaler B et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res. 2002 91:837 44.
23. Nimmanapalli R, Fuino L, Bali P et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003 63:5126 35.
24. Kent EC, Hussain MH. The patient with hormone-refractory prostate cancer: Determining who, when, and how to treat. Urology 2003 62 (Suppl 1 134 40.
25. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281:1591 7.
26. Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman R Prostate cancer chemoprevention agent development: The National Cancer Institute, Division of Cancer Prevention portfolio. J. Urol. 2004 171 (2 Pt 2 S68 74 discussion S75.
27. Ajamian F, Salminen A, Reeben M. Selective regulation of class I and class II histone deacetylases expression by inhibitors of histone deacetylases in cultured mouse neural cells. Neurosci. Lett. 2004 365:64 8.
28. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother. Pharmacol. 2001 48 (Suppl 1 S20 6.
29. Huang H, Reed CP, Zhang JS, Shridhar V, Wang L, Smith DI. Carboxypeptidase A3 (CPA3): A novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Res. 1999 59:2981 8.
30. Kramer OH, Gottlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 2001 12:294 300.
31. Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): Dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 1997 57:3697 707.
32. Loscher W. Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002 16:669 94.
33. Blaheta RA, Cinatl J Jr. Anti-tumor mechanisms of valproate: A novel role for an old drug. Med. Res. Rev. 2002 22:492 511.
34. Gottlicher M. Valproic acid: An old drug newly discovered as inhibitor of histone deacetylases. Ann. Hematol. 2004 83:S91 2.
35. Cinatl J Kotchetkov R, Blaheta R, Driever PH, Vogel JU, Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE (2) -C cells by valproic acid: Enhancement by combination with interferon-alpha. Int. J. Oncol. 2002 20:97 106.
36. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: Understanding a new wave of anticancer agents. Int. J. Cancer 2004 112:171 8.
37. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994 369:574 8.
38. Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers. J. Urol. 1997 158:636 41.
39. Myers RB, Oelschlager DK, Coan PN et al. Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma. J. Urol. 1999 161:945 9.
40. Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression. Br. J. Cancer 1999 80:546 55.
41. Craft N, Chhor C, Tran C et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999 59:5030 6.
42. Agus DB, Cordon-Cardo C, Fox W et al. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst. 1999 91:1869 76.
43. Mei S, Ho AD, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer (review). Int. J. Oncol. 2004 25:1509 19.
44. Fronsdal K, Saatcioglu F. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 2005 62:299 306.
45. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 2002 97:290 6.
46. Sawa H, Murakami H, Ohshima Y et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol. 2002 19:77 81.
47. Deroanne CF, Bonjean K, Servotte S et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002 21:427 36.
48. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE 2001 112:RE21.
49. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 1992 267:26031 7.
50. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 1991 5:1806 14.
51. Poltorak Z, Cohen T, Sivan R et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J. Biol. Chem. 1997 272:7151 8.
52. Lei J, Jiang A, Pei D. Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. Biochim. Biophys. Acta 1998 1443:400 6.
53. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J. Urol. 1997 157:2323 8.
54. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 2002 94:883 93.